Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Obeticholic acid

Brand: Ocaliva ®
NICE TA: 443
Indication: Treating primary biliary cholangitis (NICE TA443)
Disease category: Gastro-intestinal system
Commissioning responsibility: NHS England
PbR excluded: 

Background

Obeticholic acid is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in combination with ursodeoxycholic acid for people whose disease has responded inadequately to ursodeoxycholic acid or as monotherapy for people who cannot tolerate ursodeoxycholic acid. Obeticholic acid is recommended only if the company provides it with the discount agreed in the patient access scheme.
Assess the response to obeticholic acid after 12 months. Only continue if there is evidence of clinical benefit.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red